Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.

Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:367-381. doi: 10.2147/COPD.S119908. eCollection 2017.

2.

Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis.

Karbasi-Afshar R, Aslani J, Ghanei M.

Caspian J Intern Med. 2016 Spring;7(2):64-70. Review.

3.

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

Gillissen A, Haidl P, Khlhäufl M, Kroegel K, Voshaar T, Gessner C.

Dtsch Arztebl Int. 2016 May 6;113(18):311-6. doi: 10.3238/arztebl.2016.0311.

4.

Long-term outcomes in chronic obstructive pulmonary disease patients: exploring the effects of inhalatory devices and their influence on the outcome.

Fadda V, Maratea D.

Clinicoecon Outcomes Res. 2016 Apr 15;8:87-95. doi: 10.2147/CEOR.S75132. eCollection 2016.

5.

Effect of salmeterol/fluticasone combination on the dynamic changes of lung mechanics in mechanically ventilated COPD patients: a prospective pilot study.

Chen WC, Chen HH, Chiang CH, Lee YC, Yang KY.

Int J Chron Obstruct Pulmon Dis. 2016 Jan 27;11:167-74. doi: 10.2147/COPD.S94709. eCollection 2016.

6.

Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD.

Kim SA, Lee JH, Kim EK, Kim TH, Kim WJ, Lee JH, Yoon HI, Baek S, Lee JS, Oh YM, Lee SD.

Tuberc Respir Dis (Seoul). 2016 Jan;79(1):22-30. doi: 10.4046/trd.2016.79.1.22. Epub 2015 Dec 31. Erratum in: Tuberc Respir Dis (Seoul). 2016 Jul;79(3):193.

7.

Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.

Snoeck-Stroband JB, Lapperre TS, Sterk PJ, Hiemstra PS, Thiadens HA, Boezen HM, Ten Hacken NH, Kerstjens HA, Postma DS, Timens W, Sont JK; GLUCOLD Study Group.

PLoS One. 2015 Dec 10;10(12):e0143793. doi: 10.1371/journal.pone.0143793. eCollection 2015.

8.

Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis.

Festic E, Bansal V, Gupta E, Scanlon PD.

COPD. 2016 Jun;13(3):312-26. doi: 10.3109/15412555.2015.1081162. Epub 2015 Dec 8.

9.

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, Barnes NC.

Thorax. 2016 Feb;71(2):118-25. doi: 10.1136/thoraxjnl-2015-207021. Epub 2015 Nov 19.

10.

Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.

Scott DA, Woods B, Thompson JC, Clark JF, Hawkins N, Chambers M, Celli BR, Calverley P.

BMC Pulm Med. 2015 Nov 11;15:145. doi: 10.1186/s12890-015-0138-4.

11.

The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.

Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger DL, Stewart R, Baldwin M, Jones RC.

Int J Chron Obstruct Pulmon Dis. 2015 Oct 15;10:2207-17. doi: 10.2147/COPD.S91694. eCollection 2015.

12.

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D; LANTERN Investigators.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 5;10:1015-26. doi: 10.2147/COPD.S84436. eCollection 2015.

13.

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.

Gao J, Pleasants RA.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 15;10:775-89. doi: 10.2147/COPD.S80656. eCollection 2015. Review.

14.

Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.

Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N; Glisten Study Group.

Thorax. 2015 Jun;70(6):519-27. doi: 10.1136/thoraxjnl-2014-206670. Epub 2015 Apr 3.

15.

Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?

Festic E, Scanlon PD.

Am J Respir Crit Care Med. 2015 Jan 15;191(2):141-8. doi: 10.1164/rccm.201409-1654PP. Review.

16.

Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, Curren K, Balter MS, Bhutani M, Camp PG, Celli BR, Dechman G, Dransfield MT, Fiel SB, Foreman MG, Hanania NA, Ireland BK, Marchetti N, Marciniuk DD, Mularski RA, Ornelas J, Road JD, Stickland MK.

Chest. 2015 Apr;147(4):894-942. doi: 10.1378/chest.14-1676. Review.

17.

Airway wall thickness is increased in COPD patients with bronchodilator responsiveness.

Kim V, Desai P, Newell JD, Make BJ, Washko GR, Silverman EK, Crapo JD, Bhatt SP, Criner GJ; COPDGene Investigators.

Respir Res. 2014 Aug 8;15:84. doi: 10.1186/s12931-014-0084-3.

18.
19.

Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Babu KS, Kastelik JA, Morjaria JB.

Br J Clin Pharmacol. 2014 Aug;78(2):282-300. doi: 10.1111/bcp.12334. Review.

20.

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis.

Oba Y, Lone NA.

Int J Chron Obstruct Pulmon Dis. 2014 May 12;9:469-79. doi: 10.2147/COPD.S48492. eCollection 2014. Review.

Supplemental Content

Support Center